These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 22677701

  • 1. Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data.
    Gregory DL, Hicks RJ, Hogg A, Binns DS, Shum PL, Milner A, Link E, Ball DL, Mac Manus MP.
    J Nucl Med; 2012 Jul; 53(7):1007-15. PubMed ID: 22677701
    [Abstract] [Full Text] [Related]

  • 2. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer.
    Hicks RJ, Kalff V, MacManus MP, Ware RE, Hogg A, McKenzie AF, Matthews JP, Ball DL.
    J Nucl Med; 2001 Nov; 42(11):1596-604. PubMed ID: 11696627
    [Abstract] [Full Text] [Related]

  • 3. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.
    Kalff V, Hicks RJ, MacManus MP, Binns DS, McKenzie AF, Ware RE, Hogg A, Ball DL.
    J Clin Oncol; 2001 Jan 01; 19(1):111-8. PubMed ID: 11134203
    [Abstract] [Full Text] [Related]

  • 4. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data.
    Barber TW, Duong CP, Leong T, Bressel M, Drummond EG, Hicks RJ.
    J Nucl Med; 2012 Jun 01; 53(6):864-71. PubMed ID: 22582047
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.
    Acad Radiol; 2013 Jan 01; 20(1):32-40. PubMed ID: 22999369
    [Abstract] [Full Text] [Related]

  • 6. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification.
    Hicks RJ, Kalff V, MacManus MP, Ware RE, McKenzie AF, Matthews JP, Ball DL.
    J Nucl Med; 2001 Nov 01; 42(11):1605-13. PubMed ID: 11696628
    [Abstract] [Full Text] [Related]

  • 7. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
    Everitt S, Ball D, Hicks RJ, Callahan J, Plumridge N, Trinh J, Herschtal A, Kron T, Mac Manus M.
    Int J Radiat Oncol Biol Phys; 2017 Nov 15; 99(4):947-955. PubMed ID: 29063854
    [Abstract] [Full Text] [Related]

  • 8. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.
    Interact Cardiovasc Thorac Surg; 2010 Jun 15; 10(6):1009-14. PubMed ID: 20197344
    [Abstract] [Full Text] [Related]

  • 9. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH, Chiu NT, Su WC, Guo HR, Lee BF.
    Radiology; 2012 Aug 15; 264(2):559-66. PubMed ID: 22692034
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer.
    Raghunathan R, Cease K, Troeschel S, Zhao L, Gross M, Chen G, Chopra V, Ramnath N.
    Am J Clin Oncol; 2018 May 15; 41(5):513-518. PubMed ID: 27322696
    [Abstract] [Full Text] [Related]

  • 13. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
    Ohno Y, Koyama H, Yoshikawa T, Matsumoto K, Aoyama N, Onishi Y, Sugimura K.
    AJR Am J Roentgenol; 2012 Jan 15; 198(1):75-82. PubMed ID: 22194481
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Huang W, Fan M, Liu B, Fu Z, Zhou T, Zhang Z, Gong H, Li B.
    J Nucl Med; 2014 Oct 15; 55(10):1584-90. PubMed ID: 25214640
    [Abstract] [Full Text] [Related]

  • 16. Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study.
    van Loon J, Grutters J, Wanders R, Boersma L, Oellers M, Dingemans AM, Bootsma G, Geraedts W, Pitz C, Simons J, Fatah SA, Snoep G, Hochstenbag M, Lambin P, De Ruysscher D.
    Eur J Cancer; 2009 Mar 15; 45(4):588-95. PubMed ID: 19046631
    [Abstract] [Full Text] [Related]

  • 17. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer.
    Taus Á, Aguiló R, Curull V, Suárez-Piñera M, Rodríguez-Fuster A, Rodríguez de Dios N, Pijuan L, Zuccarino F, Vollmer I, Sánchez-Font A, Belda-Sanchis J, Arriola E.
    Arch Bronconeumol; 2014 Mar 15; 50(3):99-104. PubMed ID: 24360985
    [Abstract] [Full Text] [Related]

  • 18. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment.
    Mac Manus MP, Hicks RJ, Ball DL, Kalff V, Matthews JP, Salminen E, Khaw P, Wirth A, Rischin D, McKenzie A.
    Cancer; 2001 Aug 15; 92(4):886-95. PubMed ID: 11550162
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.
    Keidar Z, Haim N, Guralnik L, Wollner M, Bar-Shalom R, Ben-Nun A, Israel O.
    J Nucl Med; 2004 Oct 15; 45(10):1640-6. PubMed ID: 15471827
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.